Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 5

Treatment of hereditary angioedema with plasma-derived C1 inhibitor

Authors Michael J Prematta, Tracy Prematta, Timothy J Craig

Published 10 October 2008 Volume 2008:4(5) Pages 975—982

DOI https://doi.org/10.2147/TCRM.S3172

Review by Single-blind

Peer reviewer comments 3

Michael J Prematta, Tracy Prematta, Timothy J Craig

Section of Allergy and Immunology, Penn State University, Milton S. Hershey Medical Center, PA, USA

Background: Plasma-derived C1 inhibitor (C1-INH) concentrate is a treatment option for acute hereditary angioedema (HAE) attacks and is considered the standard-of-care in many countries, although it is not yet available in the United States. Studies are still being conducted to establish its safety and efficacy as required by the FDA.

Objective: To review the medical literature to determine if C1-INH concentrate is a safe and effective treatment for acute HAE attacks.

Methods: The following keywords were searched in PubMed and OVID: C1 esterase inhibitor, C1-inhibitor, C1 inhibitor, and hereditary angioedema treatment. English-language articles were searched from 1966 to the present to look for studies demonstrating the efficacy and the safety of C1-INH concentrate.

Results: The English-language literature search revealed several studies showing significantly improved relief of HAE symptoms with the administration of C1-INH concentrate – many studies demonstrated some improvement of symptoms within 30 minutes. Side effects have been similar to placebo, and no proven cases of viral transmission have occurred in over 20 years.

Conclusion: C1-INH concentrate appears to be a very safe and effective treatment option for HAE.

Keywords: hereditary angioedema, c1 inhibitor, c1 esterase inhibitor, hereditary angioedema treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Five-year review of an international clinical research-training program

Suemoto CK, Ismail S, Corrêa PCRP, Khawaja F, Jerves T, Pesantez L, Germani AC, Zaina F, Santos AC, Ferreira RJ, Singh P, Paulo JV, Matsubayashi SR, Vidor LP, Andretta G, Tomás R, Illigens BM, Fregni F

Advances in Medical Education and Practice 2015, 6:249-257

Published Date: 1 April 2015

Fluoromica nanoparticle cytotoxicity in macrophages decreases with size and extent of uptake

Tee N, Zhu Y, Mortimer GM, Martin DJ, Minchin RF

International Journal of Nanomedicine 2015, 10:2363-2375

Published Date: 26 March 2015

Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis

José Luis Callejas-Rubio, Lourdes López-Pérez, Norberto Ortego-Centeno

Therapeutics and Clinical Risk Management 2008, 4:1305-1313

Published Date: 5 December 2008

Treatment strategies in mucous membrane pemphigoid

Ann G Neff, Matthew Turner, Diya F Mutasim

Therapeutics and Clinical Risk Management 2008, 4:617-626

Published Date: 6 June 2008

Treating psoriasis with adalimumab

Eihab A Alwawi, Stephanie L Mehlis, Kenneth B Gordon

Therapeutics and Clinical Risk Management 2008, 4:345-351

Published Date: 11 April 2008

Raltegravir: first in class HIV integrase inhibitor

Zelalem Temesgen, Dawd S Siraj

Therapeutics and Clinical Risk Management 2008, 4:493-500

Published Date: 11 April 2008

Update on the treatment of ankylosing spondylitis

Walter P Maksymowych

Therapeutics and Clinical Risk Management 2007, 3:1125-1133

Published Date: 15 January 2008

Alendronate sodium in the management of osteoporosis

P J J Prinsloo, DJ Hosking

Therapeutics and Clinical Risk Management 2006, 2:235-249

Published Date: 15 September 2006